|
DE2927352A1
(de)
|
1979-07-06 |
1981-02-05 |
Thomae Gmbh Dr K |
In 6-stellung substituierte benzothiazol-2(3h)-one enthaltende arzneimittel
|
|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
|
GB8817743D0
(en)
|
1988-07-26 |
1988-09-01 |
Fujisawa Pharmaceutical Co |
Fr901228 substance & preparation thereof
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5545522A
(en)
|
1989-09-22 |
1996-08-13 |
Van Gelder; Russell N. |
Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
|
|
US5817667A
(en)
*
|
1991-04-17 |
1998-10-06 |
University Of Georgia Research Foudation |
Compounds and methods for the treatment of cancer
|
|
JPH064872A
(ja)
|
1992-06-19 |
1994-01-14 |
Sony Corp |
光ディスク再生装置
|
|
JPH0764872A
(ja)
|
1993-08-26 |
1995-03-10 |
Fujitsu Ten Ltd |
データ記憶制御装置
|
|
US5578832A
(en)
|
1994-09-02 |
1996-11-26 |
Affymetrix, Inc. |
Method and apparatus for imaging a sample on a device
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
|
US5556752A
(en)
|
1994-10-24 |
1996-09-17 |
Affymetrix, Inc. |
Surface-bound, unimolecular, double-stranded DNA
|
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
|
US5776905A
(en)
|
1996-08-08 |
1998-07-07 |
The Board Of Trustees Of The Leland Stamford Junior University |
Apoptotic regression of intimal vascular lesions
|
|
US6030961A
(en)
|
1997-03-11 |
2000-02-29 |
Bar-Ilan Research & Development Co., Ltd. |
Oxyalkylene phosphate compounds and uses thereof
|
|
US6124495A
(en)
|
1997-03-11 |
2000-09-26 |
Beacon Laboratories, Inc. |
Unsaturated oxyalkylene esters and uses thereof
|
|
NZ503061A
(en)
|
1997-09-02 |
2001-08-31 |
Japan Energy Corp |
Cyclic tetrapeptide derivatives and use as anti-cancer agents
|
|
US6350458B1
(en)
|
1998-02-10 |
2002-02-26 |
Generex Pharmaceuticals Incorporated |
Mixed micellar drug deliver system and method of preparation
|
|
JPH11335375A
(ja)
|
1998-05-20 |
1999-12-07 |
Mitsui Chem Inc |
ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
|
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US20070148228A1
(en)
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
|
US6723338B1
(en)
|
1999-04-01 |
2004-04-20 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
|
CN1378450A
(zh)
|
1999-09-08 |
2002-11-06 |
斯隆-凯特林癌症研究院 |
新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法
|
|
US6828302B1
(en)
|
1999-12-08 |
2004-12-07 |
Xcyte Therapies, Inc. |
Therapeutic uses of depsipeptides and congeners thereof
|
|
PT1438966E
(pt)
|
1999-12-08 |
2007-05-31 |
Cyclacel Pharmaceuticals Inc |
Uso de depsipéptidos e seus congéneres como imunosupressores para tratamento de doenças infecciosas, como uma doença autoimune, reacções alérgicas ou doença hiperproliferativa da pele.
|
|
CA2317003A1
(en)
|
2000-02-28 |
2001-08-28 |
Hidenori Nakajima |
Gene expression potentiator
|
|
JP2001348340A
(ja)
|
2000-06-07 |
2001-12-18 |
Yamanouchi Pharmaceut Co Ltd |
ヒストン脱アセチル化酵素阻害剤
|
|
WO2002006307A1
(fr)
|
2000-07-17 |
2002-01-24 |
Fujisawa Pharmaceutical Co., Ltd. |
Fk228 reduit et son utilisation
|
|
AU2001285042A1
(en)
|
2000-08-18 |
2002-03-04 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
|
|
EP1313872A1
(en)
|
2000-09-01 |
2003-05-28 |
Fujisawa Pharmaceutical Co., Ltd. |
A method of producing fr901228
|
|
AU2002243231A1
(en)
|
2000-11-21 |
2002-07-24 |
Wake Forest University |
Method of treating autoimmune diseases
|
|
EP1356053A2
(en)
|
2001-01-10 |
2003-10-29 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
|
|
US7219016B2
(en)
|
2001-04-20 |
2007-05-15 |
Yale University |
Systems and methods for automated analysis of cells and tissues
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
ATE401395T1
(de)
|
2001-05-02 |
2008-08-15 |
Univ California |
Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
|
|
CN1589135A
(zh)
|
2001-05-30 |
2005-03-02 |
密歇根大学董事会 |
Bcl－2族蛋白的小分子拮抗剂
|
|
US7171311B2
(en)
|
2001-06-18 |
2007-01-30 |
Rosetta Inpharmatics Llc |
Methods of assigning treatment to breast cancer patients
|
|
JP4238728B2
(ja)
|
2001-08-21 |
2009-03-18 |
アステラス製薬株式会社 |
ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
|
|
US20040259772A1
(en)
|
2001-08-24 |
2004-12-23 |
Antonio Fojo |
Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
|
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
|
US20050123896A1
(en)
|
2001-10-25 |
2005-06-09 |
Benz Christopher C. |
Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
|
|
WO2003038060A2
(en)
|
2001-11-01 |
2003-05-08 |
The Regents Of The University Of Michigan |
Small molecule inhibitors targeted at bcl-2
|
|
AU2002351898A1
(en)
|
2001-12-21 |
2003-07-09 |
Universite Libre De Bruxelles |
Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
|
|
US20030134423A1
(en)
|
2002-01-04 |
2003-07-17 |
Chu Yong Liang |
Compounds for delivering substances into cells
|
|
AU2003219803B8
(en)
|
2002-02-15 |
2005-08-25 |
Sloan-Kettering Institute For Cancer Research |
Method of treating TRX mediated diseases
|
|
WO2003070754A1
(fr)
|
2002-02-20 |
2003-08-28 |
Minoru Yoshida |
Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
|
|
US20040132825A1
(en)
|
2002-03-04 |
2004-07-08 |
Bacopoulos Nicholas G. |
Methods of treating cancer with HDAC inhibitors
|
|
BR0308250A
(pt)
|
2002-03-04 |
2005-01-11 |
Aton Pharma Inc |
Métodos de indução de diferenciação terminal
|
|
WO2003083067A2
(en)
|
2002-03-28 |
2003-10-09 |
Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
|
|
CA2481466A1
(en)
|
2002-04-05 |
2003-10-16 |
Yoshinori Naoe |
Depsipeptide for therapy of kidney cancer
|
|
AU2003226408B2
(en)
|
2002-04-15 |
2007-06-14 |
Sloan-Kettering Institute For Cancer Research |
Combination therapy for the treatment of cancer
|
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
|
US20040002447A1
(en)
|
2002-06-04 |
2004-01-01 |
Regents Of The University Of California |
Induction of insulin expression
|
|
WO2004009771A2
(en)
|
2002-07-24 |
2004-01-29 |
Advanced Stent Technologies, Inc. |
Stents capable of controllably releasing histone deacetylase inhibitors
|
|
JP4804004B2
(ja)
|
2002-08-20 |
2011-10-26 |
アステラス製薬株式会社 |
関節軟骨細胞外マトリクス分解阻害剤
|
|
EP1553948B1
(en)
|
2002-09-13 |
2011-08-24 |
Virginia Commonwealth University |
Combination of imatnib and a histone deacetylase inhibitor for the treatment of leukemia
|
|
SE0300098D0
(sv)
|
2003-01-15 |
2003-01-15 |
Forskarpatent I Syd Ab |
Use of cyclin D1 inhibitors
|
|
WO2004064727A2
(en)
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
|
CA2519320A1
(en)
|
2003-02-19 |
2004-09-02 |
Astellas Pharma Inc. |
Method of estimating antitumor effect of histone deacetylase inhibitor
|
|
WO2004096289A1
(ja)
|
2003-04-25 |
2004-11-11 |
Fujisawa Pharmaceutical Co |
遺伝子導入効率増強剤
|
|
US20040213826A1
(en)
|
2003-04-28 |
2004-10-28 |
Marx Steven O. |
Medical devices and methods for inhibiting proliferation of smooth muscle cells
|
|
EP1491188A1
(en)
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
|
PT2238982E
(pt)
|
2003-06-27 |
2013-01-22 |
Astellas Pharma Inc |
Agente terapêutico para o sarcoma de tecidos moles
|
|
CL2004001834A1
(es)
|
2003-07-23 |
2005-06-03 |
Bayer Pharmaceuticals Corp |
Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
|
|
US20080221080A1
(en)
*
|
2003-08-25 |
2008-09-11 |
James Douglas Griffin |
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
|
|
PL1663194T3
(pl)
|
2003-08-26 |
2011-01-31 |
Merck Hdac Res Llc |
Zastosowanie SAHA do leczenia międzybłoniaka
|
|
US20070190022A1
(en)
|
2003-08-29 |
2007-08-16 |
Bacopoulos Nicholas G |
Combination methods of treating cancer
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
WO2005027842A2
(en)
|
2003-09-18 |
2005-03-31 |
Combinatorx, Incorporated |
Combinations of drugs for the treatment of neoplasms
|
|
EP2263694B1
(en)
|
2003-09-25 |
2013-06-12 |
Astellas Pharma Inc. |
Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
|
|
US8614318B2
(en)
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
|
WO2005051430A1
(de)
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
|
|
EP1689446B1
(de)
|
2003-11-14 |
2015-01-07 |
Per Sonne Holm |
Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
|
|
WO2005053609A2
(en)
|
2003-11-26 |
2005-06-16 |
Guilford Pharmaceuticals Inc. |
Methods of nad+-dependent deacetylase inhibitors
|
|
EP1713460A2
(en)
|
2003-12-10 |
2006-10-25 |
Wisconsin Alumni Research Foundation |
Fk228 analogs and their use as hdac-inhibitors
|
|
US7951780B2
(en)
|
2004-02-25 |
2011-05-31 |
Astellas Pharma Inc. |
Antitumor agent
|
|
US20050187148A1
(en)
|
2004-02-25 |
2005-08-25 |
Yoshinori Naoe |
Antitumor agent
|
|
ATE437370T1
(de)
|
2004-02-27 |
2009-08-15 |
Us Gov Health & Human Serv |
Pharmakodynamische tests mit durchflusszytometrie
|
|
GB0405349D0
(en)
|
2004-03-10 |
2004-04-21 |
Univ Birmingham |
Cancer therapy and medicaments therefor
|
|
ITMI20040876A1
(it)
|
2004-04-30 |
2004-07-30 |
Univ Degli Studi Milano |
Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
|
|
PL1591109T3
(pl)
|
2004-04-30 |
2008-11-28 |
Topotarget Germany Ag |
Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie”
|
|
WO2005115149A2
(en)
|
2004-05-20 |
2005-12-08 |
Dow Agrosciences Llc |
Insectidal activity of a cyclic peptide
|
|
WO2005117930A2
(en)
|
2004-06-04 |
2005-12-15 |
Sloan-Kettering Institute For Cancer Research |
Use of thioredoxin measurements for diagnostics and treatments
|
|
US7470722B2
(en)
|
2004-06-10 |
2008-12-30 |
Kalypsys, Inc. |
Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
|
|
US20060018921A1
(en)
|
2004-07-16 |
2006-01-26 |
Baylor College Of Medicine |
Histone deacetylase inhibitors and cognitive applications
|
|
JP5334414B2
(ja)
|
2004-09-06 |
2013-11-06 |
バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規のピラゾロピリミジン
|
|
JP2008520682A
(ja)
*
|
2004-11-17 |
2008-06-19 |
ザ ユニヴァーシティー オヴ シカゴ |
ヒストンデアセチラーゼ阻害剤およびその使用方法
|
|
WO2006060382A2
(en)
|
2004-11-30 |
2006-06-08 |
Trustees Of The University Of Pennsylvania |
Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
|
|
WO2006060429A2
(en)
|
2004-12-03 |
2006-06-08 |
Novartis Ag |
Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
|
|
US20060128660A1
(en)
|
2004-12-10 |
2006-06-15 |
Wisconsin Alumni Research Foundation |
FK228 analogs and methods of making and using the same
|
|
GB0511266D0
(en)
|
2005-06-02 |
2005-07-13 |
Trust |
Chemical compounds
|
|
EP1743654A1
(en)
|
2005-07-15 |
2007-01-17 |
TopoTarget Germany AG |
Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
|
|
US7943568B2
(en)
|
2005-09-30 |
2011-05-17 |
The Ohio State University Research Foundation |
Antitumor agents
|
|
WO2007058896A2
(en)
|
2005-11-10 |
2007-05-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
|
|
JP2009519224A
(ja)
|
2005-11-18 |
2009-05-14 |
グロスター ファーマシューティカルズ， インコーポレイテッド |
Ｈｄａｃインヒビターｆｋ２２８の代謝産物誘導体
|
|
CA2650520A1
(en)
|
2006-04-24 |
2008-01-31 |
Gloucester Pharmaceuticals |
Treatment of ras-expressing tumors
|
|
WO2007146730A2
(en)
|
2006-06-08 |
2007-12-21 |
Gloucester Pharmaceuticals |
Deacetylase inhibitor therapy
|
|
EP2040731A4
(en)
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
|
|
US7857804B2
(en)
|
2006-09-01 |
2010-12-28 |
Mccaffrey Timothy A |
Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
|
|
WO2008083288A2
(en)
|
2006-12-29 |
2008-07-10 |
Gloucester Pharmaceuticals |
Purifiction of romidepsin
|
|
AU2007342030B2
(en)
*
|
2006-12-29 |
2013-08-15 |
Celgene Corporation |
Romidepsin-based treatments for cancer
|
|
WO2009064300A1
(en)
*
|
2007-11-15 |
2009-05-22 |
The Johns Hopkins University |
Combinations of hdac inhibitors and cytokines/growth factors
|
|
CA2732294A1
(en)
*
|
2008-07-30 |
2010-02-04 |
Gloucester Pharmaceuticals, Inc. |
Accelerated therapy
|
